Department of Medicine, Houston Methodist Hospital, Houston, TX, USA.
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
Blood Rev. 2020 Nov;44:100674. doi: 10.1016/j.blre.2020.100674. Epub 2020 Feb 26.
Cancer care advances have led to increased numbers of cancer survivors and to improved understanding of late effects of cancers and their therapies and survivorship issues. Long-term follow-up of cancer patients is crucial in preventing and managing many of the late effects of cancers and their therapies. However, the literature has highlighted the high rates of loss to follow-up (loss to FU) after cancer treatment, particularly in patients with hematologic malignancies. In this review, we performed a systematic search of published literature on issues pertaining to loss to FU in survivors of hematologic malignancies, highlighting the predictors of increased or decreased rates of loss to FU. We found that the literature on survivors of adulthood cancers is very limited, in contrast to articles discussing young adult survivors of childhood cancers. Predictors and barriers of loss to FU were found to be variable in different studies; however, they shared some common themes, including disease-related, logistic, financial and educational factors. Furthermore, we discuss the potential interventions to mitigate the loss to FU, along with discussing research priorities in this area.
癌症治疗的进展使得癌症幸存者的数量增加，并且对癌症及其治疗的晚期效应和生存问题有了更好的认识。对癌症患者进行长期随访对于预防和管理许多癌症及其治疗的晚期效应至关重要。然而，文献强调了癌症治疗后随访丢失（FU 丢失）的高发生率，尤其是在血液恶性肿瘤患者中。在这篇综述中，我们对有关血液恶性肿瘤幸存者 FU 丢失问题的已发表文献进行了系统检索，重点强调了增加或降低 FU 丢失率的预测因素。我们发现，与讨论儿童期癌症成年幸存者的文章相比，有关成年癌症幸存者的文献非常有限。在不同的研究中，FU 丢失的预测因素和障碍各不相同；但是，它们也有一些共同的主题，包括与疾病相关的、后勤、财务和教育因素。此外，我们还讨论了减轻 FU 丢失的潜在干预措施，并讨论了该领域的研究重点。
